Drugs / AZD8055
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01316809 | Mar 2011 → Apr 2014 | anaplastic astrocytoma, anaplastic oligodendroglioma, brain stem glioma, glioblastoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00999882 | Oct 2009 → Dec 2011 | hepatocellular carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00973076 | Aug 2009 → Dec 2010 | cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00731263 | Jul 2008 → Nov 2010 | cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01194193 | — | cancer, lymphoma | AstraZeneca | Withdrawn | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD8055 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00731263 ↗ |
| Known as | AZ-12600000 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1801204 ↗ |
| Action | Inhibit | “Tor kinase inhibitor AZD8055” NCT00731263 ↗ |
| Modality | Small molecule | — CHEMBL1801204 ↗ |
| Route | Oral | “AZD8055 will be administered orally” NCT00973076 ↗ |
| Target | MTOR | “a first-in-class dual mTORC1/2 inhibitor” PMID 22843211 ↗ Jul 2012 |